Think most investors following Synergy Pharma (SGYP) are shocked that the stock is trading down at $4.50 at the launch of Trulance. Lots of questions remain whether this is the correct launch strategy.With an approved CIC drug with a favorable safety profile over a successful drug like Linzess from Ironwood Pharma (IRWD), Synergy has to be a buyout target on this dip. Think lots of questions exist on whether direct to consumer marketing is a required route, but so much value exists to bypass the stock here with a market cap of $1 billion . Disclosure: No position